Page last updated: 2024-10-27

gabexate and Lung Diseases

gabexate has been researched along with Lung Diseases in 1 studies

Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.

Lung Diseases: Pathological processes involving any part of the LUNG.

Research Excerpts

ExcerptRelevanceReference
"Sixty-one patients operated for esophageal cancer from 1996 to 2000 were treated postoperatively with low dose dopamine (300 microg/kg/h), gabexate mesilate (80 mg/h), and ulinastatin (300 000 unit/day) as a study group."1.33Use of low dose dopamine, gabexate mesilate and ulinastatin reduces the water balance and pulmonary complication in thoracic esophagectomy patients. ( Fujii, Y; Ishiguro, H; Kimura, M; Kuwabara, Y; Sato, A; Shinoda, N, 2005)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sato, A1
Kuwabara, Y1
Shinoda, N1
Kimura, M1
Ishiguro, H1
Fujii, Y1

Other Studies

1 other study available for gabexate and Lung Diseases

ArticleYear
Use of low dose dopamine, gabexate mesilate and ulinastatin reduces the water balance and pulmonary complication in thoracic esophagectomy patients.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2005, Volume: 18, Issue:3

    Topics: Carcinoma, Squamous Cell; Dopamine; Esophageal Neoplasms; Esophagectomy; Gabexate; Glycoproteins; Hu

2005